Global Information
회사소개 | 문의 | 비교리스트

중증하지허혈 치료 시장(기기별 : 색전 예방 기기, 말초 확장 시스템, 의약품) - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2019-2027년)

Critical Limb Ischemia Treatment Market (Devices (Embolic Protection Devices, Peripheral Dilatation Systems, Medications ) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

리서치사 Transparency Market Research
발행일 2019년 05월 상품 코드 881229
페이지 정보 영문 166 Pages
가격
US $ 5,795 ₩ 6,994,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 인쇄는 가능하지만, 전체 페이지 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,795 ₩ 10,615,000 PDF (5-user License) help
5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 전체 페이지 인쇄는 1명당 1회로 한정하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,795 ₩ 14,236,000 PDF (Corporate License) help
기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


중증하지허혈 치료 시장(기기별 : 색전 예방 기기, 말초 확장 시스템, 의약품) - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2019-2027년) Critical Limb Ischemia Treatment Market (Devices (Embolic Protection Devices, Peripheral Dilatation Systems, Medications ) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
발행일 : 2019년 05월 페이지 정보 : 영문 166 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 중증하지허혈 치료(Critical Limb Ischemia Treatment) 시장에 대해 조사했으며, 시장 동향과 기회, 성장 촉진요인 및 저해요인, 치료 및 지역별 시장 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 서론

  • 보고 범위와 시장 세분화
  • 조사 하이라이트

제2장 전제조건과 조사 방법

  • 전제조건과 사용된 약어
  • 조사 방법

제3장 주요 요약

제4장 시장 개요

  • 제품 개요
  • 시장 동향
    • 성장 촉진요인 및 저해요인 현황 분석
    • 성장 촉진요인
    • 성장 저해요인
    • 시장 기회
  • 시장 판매 예측(100만 달러)
  • 시장 전망

제5장 시장 전망

  • 파이프라인 분석
  • 주요 산업 이벤트
  • 기기 규제 시나리오
  • 세계/지역별 중증 하지허혈 유병률
  • 주요 연구기관
  • 기술의 진보

제6장 세계의 중증하지허혈 치료 시장 분석 : 치료별

  • 주요 조사결과
  • 서론
  • 시장 판매 점유율과 매력 분석
  • 시장 예측
    • 기기
    • 약물
  • 시장 분석

제7장 세계의 중증하지허혈 치료 시장 분석 : 지역별

  • 시장 시나리오
  • 시장 판매 점유율과 매력 분석
  • 시장 예측
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카

제8장 북미

제9장 유럽

제10장 아시아태평양

제11장 라틴아메리카

제12장 중동 및 아프리카

제13장 경쟁 구도

  • 경쟁 매트릭스
  • 기업 개요
    • Medtronic plc
    • Boston Scientific Corporation
    • Cesca Therapeutics, Inc.
    • Abbott Laboratories
    • Pluristem Therapeutics, Inc.
    • Rexgenero Ltd.
    • LimFlow SA
    • Micro Medical Solutions
    • Cardiovascular System, Inc.
LSH 19.07.16

List of Tables

  • Table 01: Pipeline Analysis
  • Table 02: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • Table 03: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • Table 04: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • Table 05: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • Table 06: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Region, 2017-2027
  • Table 07: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country, 2017-2027
  • Table 08: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • Table 09: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2017-2027
  • Table 10: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation Systems, 2017-2027
  • Table 11: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medications, 2017-2027
  • Table 12: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 13: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • Table 14: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2017-2027
  • Table 15: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation Systems, 2017-2027
  • Table 16: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medications, 2017-2027
  • Table 17: Asia Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 19: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • Table 20: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2017-2027
  • Table 21: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation Systems, 2017-2027
  • Table 22: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medications, 2017-2027
  • Table 23: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 24: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • Table 25: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2017-2027
  • Table 26: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation Systems, 2017-2027
  • Table 27: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medications, 2017-2027
  • Table 28: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 29: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • Table 30: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2017-2027
  • Table 31: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation Systems, 2017-2027
  • Table 32: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medications, 2017-2027
  • Table 33: Medtronic plc, Business Overview
  • Table 34: Boston Scientific Corporation Product Offerings
  • Table 35: Cesca Therapeutics, Inc., Products & Services Offered
  • Table 36: Abbott Laboratories, Business Overview
  • Table 37: Pluristem Therapeutics, Inc., Products & Services Offered
  • Table 38: Rexgenero Ltd., Products & Services Offered
  • Table 39: LimFlow SA, Products & Services Offered
  • Table 40: Micro Medical Solutions, Products & Services Offered
  • Table 41: Cardiovascular Systems, Inc., Products & Services Offered

List of Figures

  • Figure 01: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027
  • Figure 02: Global Critical Limb Ischemia Treatment Market Revenue Projection (US$ Mn), 2017-2027
  • Figure 03: Global Critical Limb Ischemia Treatment Market Value Share, by Treatment, 2018
  • Figure 04: Global Critical Limb Ischemia Treatment Market Value Share, by Region, 2018
  • Figure 05: U.S. FDA Medical Devices Approval Criteria
  • Figure 06: Classification of Medical Devices
  • Figure 07: European Approval for Medical Devices - Regulatory Pathway (Class IIb Devices only)
  • Figure 08: Regulatory Approval Process - U.S.
  • Figure 09: Regulatory Approval Process - Europe
  • Figure 10: Regulatory Approval Process - Japan
  • Figure 11: Prevalence of Critical Limb Ischemia Globally/Region
  • Figure 12: Global Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • Figure 13: Global Critical Limb Ischemia Treatment Market Attractiveness, by Treatment, 2019-2027
  • Figure 14: Global Critical Limb Ischemia Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Devices, 2017-2027
  • Figure 15: Global Critical Limb Ischemia Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Medications, 2017-2027
  • Figure 16: Global Critical Limb Ischemia Treatment Market Scenario, by Country
  • Figure 17: Global Critical Limb Ischemia Treatment Market Value Share, by Region, 2018 and 2027
  • Figure 18: Global Critical Limb Ischemia Treatment Market Attractiveness, by Region, 2019-2027
  • Figure 19: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019-2027
  • Figure 20: North America Critical Limb Ischemia Treatment Market Value Share Analysis, by Country, 2018 and 2027
  • Figure 21: North America Critical Limb Ischemia Treatment Market Attractiveness, by Country, 2019-2027
  • Figure 22: North America Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • Figure 23: North America Critical Limb Ischemia Treatment Market Attractiveness, by Treatment, 2019-2027
  • Figure 24: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019-2027
  • Figure 25: Europe Critical Limb Ischemia Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 26: Europe Critical Limb Ischemia Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • Figure 27: Europe Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • Figure 28: Europe Critical Limb Ischemia Treatment Market Attractiveness, by Treatment, 2019-2027
  • Figure 29: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019-2027
  • Figure 30: Asia Pacific Critical Limb Ischemia Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 31: Asia Pacific Critical Limb Ischemia Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • Figure 32: Asia Pacific Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • Figure 33: Asia Pacific Critical Limb Ischemia Treatment Market Attractiveness, by Treatment, 2019-2027
  • Figure 34: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019-2027
  • Figure 35: Latin America Critical Limb Ischemia Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 36: Latin America Critical Limb Ischemia Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • Figure 37: Latin America Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • Figure 38: Latin America Critical Limb Ischemia Treatment Market Attractiveness, by Treatment, 2019-2027
  • Figure 39: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019-2027
  • Figure 40: Middle East & Africa Critical Limb Ischemia Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 41: Middle East & Africa Critical Limb Ischemia Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • Figure 42: Middle East & Africa Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • Figure 43: Middle East & Africa Critical Limb Ischemia Treatment Market Attractiveness, by Treatment, 2019-2027
  • Figure 44: Medtronic plc, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 45: Medtronic plc, Breakdown of Net Sales (%), by Geography, 2018
  • Figure 46: Medtronic plc, Breakdown of Net Sales (%), by Business Segment, 2018
  • Figure 47: Medtronic plc, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 48: Boston Scientific Corporation, Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • Figure 49: Boston Scientific Corporation, Breakdown of Net Sales, by Region, 2017
  • Figure 50: Boston Scientific Corporation, Breakdown of Net Sales, by Business Segment, 2017
  • Figure 51: Cesca Therapeutics Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 52: Cesca Therapeutics Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 53: Cesca Therapeutics Inc. Breakdown of Net Sales, by Region, 2018
  • Figure 54: Cesca Therapeutics Inc. Sales & Marketing Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 55: Abbott Laboratories, Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
  • Figure 56: Abbott Laboratories, R&D Intensity and Sales & Marketing Intensity (US$ Mn), 2016-2018
  • Figure 57: Abbott Laboratories, Breakdown of Net Sales, by Countries, 2018
  • Figure 58: Abbott Laboratories, Breakdown of Net Sales, by Business Segment, 2018
  • Figure 59: Cardiovascular Systems, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 60: Cardiovascular Systems, Inc. R&D Intensity and Sales & Marketing Intensity (US$ Mn), 2016-2018

Title:
Critical Limb Ischemia Treatment Market (Devices (Embolic Protection Devices, Peripheral Dilatation Systems (Balloon Dilators, Vascular stents), Medications (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents)) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027.

Global Critical Limb Ischemia Treatment Market: Overview

This report analyzes the current and future scenario of the global critical limb ischemia treatment market. Increase in patient population with critical limb ischemia, growth of the pharmaceutical industry, improvement in health care infrastructure, and increase in the number of clinical trials are projected to be the major drivers of the global market during the forecast period.

The global critical limb ischemia treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global critical limb ischemia treatment market.

Global Critical Limb Ischemia Treatment Market: Key Segments

Based on treatment, the global critical limb ischemia treatment market has been segmented into devices and medications. The segments have been analyzed based on available devices and drug products used in the treatment of critical limb ischemia, cost-effectiveness, and preference for industries. The market size and forecast for each of these segments have been provided for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year.

Global Critical Limb Ischemia Treatment Market: Regional Outlook

In terms of region, the global critical limb ischemia treatment market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global critical limb ischemia treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players profiled in the market report include Medtronic plc, Boston Scientific Corporation, Cesca Therapeutics, Inc., Abbott Laboratories, Pluristem Therapeutics, Inc., Rexgenero Ltd., LimFlow SA, Micro Medical Solutions, and Cardiovascular Systems, Inc.

The global critical limb ischemia treatment market has been segmented as below:

  • Global Critical Limb Ischemia Treatment Market, by Treatment
  • Devices
  • Embolic Protection Devices
  • Peripheral Dilatation Systems
  • Balloon Dilators
  • Vascular stents
  • Medications
  • Antiplatelet Drugs
  • Antihypertensive Agents
  • Lipid-lowering Agents
  • Antithrombotic Agents
  • Others
  • Global Critical Limb Ischemia Treatment Market, by Region
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • Italy
  • France
  • Spain
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Assumptions and Acronyms Used
  • 2.2. Research Methodology

3. Executive Summary

4. Market Overview

  • 4.1. Product Overview
  • 4.2. Market Dynamics
    • 4.2.1. Drivers and Restraints Snapshot Analysis
    • 4.2.2. Drivers
    • 4.2.3. Restraints
    • 4.2.4. Opportunity
  • 4.3. Global Critical Limb Ischemia Treatment Market Revenue Projection (US$ Mn), 2017-2027
  • 4.4. Global Critical Limb Ischemia Treatment Market Outlook

5. Market Outlook

  • 5.1. Pipeline Analysis
  • 5.2. Key Industry Events
  • 5.3. Regulatory Scenario for Device
  • 5.4. Prevalence of Critical Limb Ischemia Globally/Region
  • 5.5. Major Research Institutes Involved
  • 5.6. Technological Advancement

6. Global Critical Limb Ischemia Treatment Market Analysis, by Treatment

  • 6.1. Key Findings
  • 6.2. Introduction
  • 6.3. Global Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
  • 6.4. Global Critical Limb Ischemia Treatment Market Forecast, by Treatment
    • 6.4.1. Devices
      • 6.4.1.1. Embolic Protection Devices
      • 6.4.1.2. Peripheral Dilatation Systems
        • 6.4.1.2.1. Balloon Dilators
        • 6.4.1.2.2. Vascular stents
    • 6.4.2. Medications
      • 6.4.2.1. Antiplatelet Drugs
      • 6.4.2.2. Antihypertensive Agents
      • 6.4.2.3. Lipid-lowering Agents
      • 6.4.2.4. Antithrombotic Agents
      • 6.4.2.5. Others
  • 6.5. Global Critical Limb Ischemia Treatment Market Analysis, by Treatment

7. Global Critical Limb Ischemia Treatment Market Analysis, by Region

  • 7.1. Global Critical Limb Ischemia Treatment Market Scenario, by Country
  • 7.2. Global Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Region
  • 7.3. Global Critical Limb Ischemia Treatment Market Forecast, by Region
    • 7.3.1. North America
    • 7.3.2. Europe
    • 7.3.3. Asia Pacific
    • 7.3.4. Latin America
    • 7.3.5. Middle East & Africa

8. North America Critical Limb Ischemia Treatment Market Analysis

  • 8.1. Key Findings
  • 8.2. North America Critical Limb Ischemia Treatment Market Overview
  • 8.3. North America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country
  • 8.4. North America Critical Limb Ischemia Treatment Market Forecast, by Country
    • 8.4.1. U.S.
    • 8.4.2. Canada
  • 8.5. North America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
  • 8.6. North America Critical Limb Ischemia Treatment Market Forecast, by Treatment
    • 8.6.1. Devices
      • 8.6.1.1. Embolic Protection Devices
      • 8.6.1.2. Peripheral Dilatation Systems
        • 8.6.1.2.1. Balloon Dilators
        • 8.6.1.2.2. Vascular stents
    • 8.6.2. Medications
      • 8.6.2.1. Antiplatelet Drugs
      • 8.6.2.2. Antihypertensive Agents
      • 8.6.2.3. Lipid-lowering Agents
      • 8.6.2.4. Antithrombotic Agents
      • 8.6.2.5. Others

9. Europe Critical Limb Ischemia Treatment Market Analysis

  • 9.1. Key Findings
  • 9.2. Europe Critical Limb Ischemia Treatment Market Overview
  • 9.3. Europe Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 9.4. Europe Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. U.K.
    • 9.4.4. Italy
    • 9.4.5. Spain
    • 9.4.6. Rest of Europe
  • 9.5. Europe Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
  • 9.6. Europe Critical Limb Ischemia Treatment Market Forecast, by Treatment
    • 9.6.1. Devices
      • 9.6.1.1. Embolic Protection Devices
      • 9.6.1.2. Peripheral Dilatation Systems
        • 9.6.1.2.1. Balloon Dilators
        • 9.6.1.2.2. Vascular stents
    • 9.6.2. Medications
      • 9.6.2.1. Antiplatelet Drugs
      • 9.6.2.2. Antihypertensive Agents
      • 9.6.2.3. Lipid-lowering Agents
      • 9.6.2.4. Antithrombotic Agents
      • 9.6.2.5. Others

10. Asia Pacific Critical Limb Ischemia Treatment Market Analysis

  • 10.1. Key Findings
  • 10.2. Asia Pacific Critical Limb Ischemia Treatment Market Overview
  • 10.3. Asia Pacific Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 10.4. Asia Pacific Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
    • 10.4.1. Japan
    • 10.4.2. China
    • 10.4.3. India
    • 10.4.4. Australia & New Zealand
    • 10.4.5. Rest of Asia Pacific
  • 10.5. Asia Pacific Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
  • 10.6. Asia Pacific Critical Limb Ischemia Treatment Market Forecast, by Treatment
    • 10.6.1. Devices
      • 10.6.1.1. Embolic Protection Devices
      • 10.6.1.2. Peripheral Dilatation Systems
        • 10.6.1.2.1. Balloon Dilators
        • 10.6.1.2.2. Vascular stents
    • 10.6.2. Medications
      • 10.6.2.1. Antiplatelet Drugs
      • 10.6.2.2. Antihypertensive Agents
      • 10.6.2.3. Lipid-lowering Agents
      • 10.6.2.4. Antithrombotic Agents
      • 10.6.2.5. Others

11. Latin America Critical Limb Ischemia Treatment Market Analysis

  • 11.1. Key Findings
  • 11.2. Latin America Critical Limb Ischemia Treatment Market Overview
  • 11.3. Latin America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 11.4. Latin America Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
    • 11.4.1. Brazil
    • 11.4.2. Mexico
    • 11.4.3. Rest of Latin America
  • 11.5. Latin America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
  • 11.6. Latin America Critical Limb Ischemia Treatment Market Forecast, by Treatment
    • 11.6.1. Devices
      • 11.6.1.1. Embolic Protection Devices
      • 11.6.1.2. Peripheral Dilatation Systems
        • 11.6.1.2.1. Balloon Dilators
        • 11.6.1.2.2. Vascular stents
    • 11.6.2. Medications
      • 11.6.2.1. Antiplatelet Drugs
      • 11.6.2.2. Antihypertensive Agents
      • 11.6.2.3. Lipid-lowering Agents
      • 11.6.2.4. Antithrombotic Agents
      • 11.6.2.5. Others

12. Middle East & Africa Critical Limb Ischemia Treatment Market Analysis

  • 12.1. Key Findings
  • 12.2. Middle East & Africa Critical Limb Ischemia Treatment Market Overview
  • 12.3. Middle East & Africa Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 12.4. Middle East & Africa Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
    • 12.4.1. GCC Countries
    • 12.4.2. South Africa
    • 12.4.3. Rest of Middle East & Africa
  • 12.5. Middle East & Africa Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
  • 12.6. Middle East & Africa Critical Limb Ischemia Treatment Market Forecast, by Treatment
    • 12.6.1. Devices
      • 12.6.1.1. Embolic Protection Devices
      • 12.6.1.2. Peripheral Dilatation Systems
        • 12.6.1.2.1. Balloon Dilators
        • 12.6.1.2.2. Vascular stents
    • 12.6.2. Medications
      • 12.6.2.1. Antiplatelet Drugs
      • 12.6.2.2. Antihypertensive Agents
      • 12.6.2.3. Lipid-lowering Agents
      • 12.6.2.4. Antithrombotic Agents
      • 12.6.2.5. Others

13. Competition Landscape

  • 13.1. Competition Matrix
  • 13.2. Company Profile
    • 13.2.1. Medtronic plc
      • 13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.2.1.2. Financial Overview
      • 13.2.1.3. Product Portfolio
      • 13.2.1.4. SWOT Analysis
      • 13.2.1.5. Strategic Overview
    • 13.2.2. Boston Scientific Corporation
      • 13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.2.2.2. Financial Overview
      • 13.2.2.3. Product Portfolio
      • 13.2.2.4. SWOT Analysis
      • 13.2.2.5. Strategic Overview
    • 13.2.3. Cesca Therapeutics, Inc.
      • 13.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.2.3.2. Financial Overview
      • 13.2.3.3. Product Portfolio
      • 13.2.3.4. SWOT Analysis
      • 13.2.3.5. Strategic Overview
    • 13.2.4. Abbott Laboratories
      • 13.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.2.4.2. Financial Overview
      • 13.2.4.3. Product Portfolio
      • 13.2.4.4. SWOT Analysis
      • 13.2.4.5. Strategic Overview
    • 13.2.5. Pluristem Therapeutics, Inc.
      • 13.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.2.5.2. Financial Overview
      • 13.2.5.3. Product Portfolio
      • 13.2.5.4. SWOT Analysis
      • 13.2.5.5. Strategic Overview
    • 13.2.6. Rexgenero Ltd.
      • 13.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.2.6.2. Financial Overview
      • 13.2.6.3. Product Portfolio
      • 13.2.6.4. SWOT Analysis
      • 13.2.6.5. Strategic Overview
    • 13.2.7. LimFlow SA
      • 13.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.2.7.2. Financial Overview
      • 13.2.7.3. Product Portfolio
      • 13.2.7.4. SWOT Analysis
      • 13.2.7.5. Strategic Overview
    • 13.2.8. Micro Medical Solutions
      • 13.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.2.8.2. Financial Overview
      • 13.2.8.3. Product Portfolio
      • 13.2.8.4. SWOT Analysis
      • 13.2.8.5. Strategic Overview
    • 13.2.9. Cardiovascular System, Inc.
      • 13.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.2.9.2. Financial Overview
      • 13.2.9.3. Product Portfolio
      • 13.2.9.4. SWOT Analysis
      • 13.2.9.5. Strategic Overview
Back to Top
전화 문의
F A Q